United Therapeutics

$241.90 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Stock Analysis

last close $241.9
1-mo return 7.1%
3-mo return 30.4%
avg daily vol. 504.75T
52-week high 244.83
52-week low 158.38
market cap. $10.8B
forward pe 14.3
annual div. -
roe 18%
ltg forecast -
dividend yield -
annual rev. $1.8B
inst own. 99.8%

Subscribe now for daily local and international financial news